Edition:
United States

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Global Market

1.04USD
8 Dec 2017
Change (% chg)

$0.04 (+4.00%)
Prev Close
$1.00
Open
$1.00
Day's High
$1.05
Day's Low
$1.00
Volume
148,306
Avg. Vol
155,467
52-wk High
$10.00
52-wk Low
$0.80

Select another date:

Wed, Dec 6 2017

BRIEF-Egalet Says Notified Verbally By CVS Caremark That Sprix Will No Longer Be On Formulary For A Portion Of Commercial Covered Lives Beginning 2018

* EGALET - NOTIFIED VERBALLY BY CVS CAREMARK THAT SPRIX WILL NO LONGER BE ON FORMULARY FOR A PORTION OF COMMERCIAL COVERED LIVES BEGINNING JAN 1, 2018

BRIEF-Egalet Corp's Phase 3 Study Of Egalet-002 In Patients With Moderate-To-Severe Chronic Low Back Pain Meets Primary Endpoint​

* EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF EGALET-002 IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN

BRIEF-Egalet Corp Says ‍Apotex Has Lost Right To Launch An Authorized Generic Version Of Sprix Nasal Spray​

* EGALET CORP - ‍COMPANY DID NOT RECEIVE ANY WRITTEN NOTIFICATION ON OR BEFORE NOTIFICATION DEADLINE FOR PRODUCT LAUNCH FROM APOTEX CORP & APOTEX INC​

BRIEF-EGALET ANNOUNCES LATE-STAGE STUDY DATA ON EGALET-002

* EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 SAFETY STUDY EVALUATING SAFETY OF EGALET-002

BRIEF-Egalet announces ARYMO ER added to large payer Medicare Part D Formulary

* A large payer will provide coverage of ARYMO ER extended-release tablets for oral use -CII for its Medicare Part D Members​

BRIEF-Highbridge Capital Management LLC reports 9.58 pct passive stake in Egalet Corp as of July 6 - SEC filing

* Highbridge Capital Management LLC reports a 9.58 percent passive stake in Egalet Corp as of July 6, 2017 - SEC filing Source text: (http://bit.ly/2u2N9mR) Further company coverage:

BRIEF-Egalet announces pricing of public offering of common stock and warrants

* Egalet announces pricing of public offering of common stock and warrants

BRIEF-Egalet receives complete response letter from US FDA for prior approval supplement for 10 mg and 15 mg dosage strengths of oxaydo

* Egalet receives complete response letter from U.S. Food and Drug Administration for prior approval supplement for 10 mg and 15 mg dosage strengths of Oxaydo

Select another date: